Application strategies of the third-generation EGFR-TKI in the context of precision medicine
10.3760/cma.j.issn.0253-3766.2017.02.002
- VernacularTitle: 精准医学背景下第三代表皮生长因子受体酪氨酸激酶抑制剂的应用策略
- Author:
Jing ZHAO
1
;
Shijia ZHANG
1
;
Caicun ZHOU
1
Author Information
1. Department of Medical Oncology, Shanghai Pulmomary Hospital, Tongji University School of Medicine, Shanghai 200433, China
- Publication Type:Review
- Keywords:
Carcinoma, non-small-cell lung;
Epidermal growth factor receptor;
Tyrosine kinase inhibitor;
Precision medicine
- From:
Chinese Journal of Oncology
2017;39(2):86-89
- CountryChina
- Language:Chinese
-
Abstract:
With the advances in molecular detection technology and the emergence of various targeted agents, we have entered the era of precision medicine across the whole process of cancer diagnosis and treatment. Tyrosine kinase inhibitors targeting epidermal growth factor receptor gene mutation, the most common driver, have been developed from the first generation to the third generation, improving the survival and life quality of patients with advanced non-small cell lung cancer. It is critically important how to rank these targeted agents and arrange combination therapies, and this review will focus on the strategies of the third-generation EGFR-TKI in the context of precision medicine.
